RecruitingNCT07312162
Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots
Sponsor
University of Southern California
Enrollment
730 participants
Start Date
Jan 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates barriers to early detection of liver cancer.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study explores why certain neighbourhoods in Los Angeles have higher rates of late-stage liver cancer (hepatocellular carcinoma, or HCC) and why people in lower-income areas tend to be diagnosed later. It collects health, social, and neighbourhood data from patients to identify barriers to early detection.
**You may be eligible if...**
- You are 18 or older
- You have been newly diagnosed with liver cancer (HCC)
- You live in a neighbourhood identified as a 'late-stage hotspot' in Los Angeles County
- You are on Medicaid or uninsured
- You speak English, Spanish, or Chinese
**You may NOT be eligible if...**
- You live outside Los Angeles County
- You have a liver tumour that is not HCC
- You are currently incarcerated
- You are pregnant
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07312162
Related Trials
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
NCT044727671 location
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
NCT072747741 location
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
NCT069022461 location
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
NCT065031461 location
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
NCT067102231 location